LPL Financial LLC boosted its holdings in Haemonetics Co. (NYSE:HAE) by 4.0% in the 4th quarter, Holdings Channel reports. The firm owned 11,644 shares of the medical instruments supplier’s stock after purchasing an additional 448 shares during the period. LPL Financial LLC’s holdings in Haemonetics were worth $1,165,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds have also added to or reduced their stakes in the company. DekaBank Deutsche Girozentrale raised its position in Haemonetics by 18.7% in the 3rd quarter. DekaBank Deutsche Girozentrale now owns 13,749 shares of the medical instruments supplier’s stock valued at $1,513,000 after purchasing an additional 2,165 shares during the last quarter. HealthCor Management L.P. purchased a new stake in Haemonetics in the 3rd quarter valued at $34,287,000. LSV Asset Management purchased a new stake in Haemonetics in the 3rd quarter valued at $294,000. Vanguard Group Inc raised its position in Haemonetics by 1.9% in the 3rd quarter. Vanguard Group Inc now owns 5,619,707 shares of the medical instruments supplier’s stock valued at $643,906,000 after purchasing an additional 107,357 shares during the last quarter. Finally, Riverhead Capital Management LLC raised its position in Haemonetics by 27.8% in the 3rd quarter. Riverhead Capital Management LLC now owns 5,971 shares of the medical instruments supplier’s stock valued at $684,000 after purchasing an additional 1,300 shares during the last quarter. Hedge funds and other institutional investors own 98.13% of the company’s stock.
Several analysts recently commented on HAE shares. Barrington Research upped their price target on shares of Haemonetics to $112.00 and gave the company a “positive” rating in a research report on Wednesday, February 6th. ValuEngine downgraded shares of Haemonetics from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 5th. Finally, Zacks Investment Research downgraded shares of Haemonetics from a “buy” rating to a “sell” rating in a research report on Tuesday, January 8th. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $119.75.
Shares of Haemonetics stock opened at $86.75 on Friday. The firm has a market cap of $4.43 billion, a price-to-earnings ratio of 46.39, a PEG ratio of 2.80 and a beta of 0.89. The company has a quick ratio of 1.64, a current ratio of 2.44 and a debt-to-equity ratio of 0.51. Haemonetics Co. has a one year low of $70.86 and a one year high of $117.56.
Haemonetics (NYSE:HAE) last announced its quarterly earnings data on Tuesday, February 5th. The medical instruments supplier reported $0.63 EPS for the quarter, topping the Zacks’ consensus estimate of $0.59 by $0.04. The company had revenue of $247.36 million during the quarter, compared to the consensus estimate of $250.12 million. Haemonetics had a net margin of 4.84% and a return on equity of 17.05%. Haemonetics’s quarterly revenue was up 5.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.62 EPS. On average, equities research analysts forecast that Haemonetics Co. will post 2.33 earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: This news story was first reported by Ticker Report and is the property of of Ticker Report. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright laws. The legal version of this news story can be read at https://www.tickerreport.com/banking-finance/4223370/lpl-financial-llc-grows-position-in-haemonetics-co-hae.html.
Haemonetics Company Profile
Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers automated plasma collection devices and related disposables, including NexSys PCS plasmapheresis system and PCS2 equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system.
Want to see what other hedge funds are holding HAE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Co. (NYSE:HAE).
Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.